| Congresso Brasileiro de Microbiologia 2023 | Resumo: 244-1 | ||||
Resumo:Periodontitis is a significant public health concern and a risk factor for severe systemic dysfunctions. Current treatment approaches focus on eliminating the source of inflammation or infection through local surgical interventions, while systemic antibiotic use is generally reserved for cases with evidence of spreading infection. However, antibiotics are frequently prescribed even in the absence of such signs. Uncontrolled antibiotic usage can lead to prolonged exposure of bacteria to sublethal concentrations, thereby promoting antibiotic resistance. Within the scope of medicinal plants, Cannabis sativa stands out as a potential source of antimicrobial compounds, with Cannabidiol (CBD) being of particular interest to researchers. CBD is well-known for its anti-inflammatory, analgesic, anxiolytic, and antimicrobial properties, which suggest its therapeutic potential. The present study aimed to evaluate the CBD antibiofilm activity against periodontopathogens, as well as its toxicity. The Minimum Inhibitory Concentration of Biofilm (MICB50) assay was employed to determine the CBD concentration required to inhibit biofilm growth by at least 50%. Biofilm cell viability was assessed by using colony counts (Log10 CFU/mL). The study included the following bacteria: Actinomyces naeslundii (ATCC 19039), Peptostreptococcus anaerobius (ATCC 27337), Aggregatibacter actinomycetencomitans (ATCC 43717), Veillonella parvula (ATCC 17745), and Fusobacterium nucleatum (ATCC 10953). The CBD used in this study was obtained from Cannabis sativa extract provided by researchers at the Federal University of São João del-Rei. CBD toxicity was evaluated by considering the the Caenorhabditis elegans survival rate and the lethal concentration of 50% (LC50). CBD exhibited MICB50 of 0.78 μg/mL against P. anaerobius, A. actinomycetencomitans, and F. nucleatum; 0.39 μg/mL against V. parvula; and 1.56 μg/mL against A. naeslundii. CBD at 1.56, 3.12, 50, and 3.12 μg/mL eliminated F. nucleatum, P. anaerobius, A. naeslundii, and A. actinomycetencomitans cell viability, respectively. In terms of toxicity assessment, CBD resulted in LC50 at the highest tested concentration (6,000 μg/mL). These findings indicate that CBD has significantly higher LC50 than MICB50 values and concentrations needed to eliminate cell viability during biofilm formation. Consequently, CBD can be considered a non-toxic compound with antibiofilm activity and holds promise as a therapeutic alternative against periodontitis. Palavras-chave: Cannabis sativa, antibiofilm activity, C elegans, toxicity, CBD Agência de fomento:Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES finance code 001), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). | |||||